Cloniprazepam
Cloniprazepam is a designer benzodiazepine, the N-cyclopropylmethyl analogue of clonazepam. It is a potent, long-acting sedative and anxiolytic with no clinical study in humans, sold only as a research chemical.
01 Overview
Cloniprazepam is derived from clonazepam by addition of a cyclopropylmethyl group. It appeared on the research-chemical market as an unapproved analogue and has no formal pharmacology or safety data in humans.
It acts at the GABA-A benzodiazepine site and is reported to be potent with a long duration, producing strong sedation, anxiolysis and amnesia. Unregulated purity, potency uncertainty and long duration make oversedation and dependence realistic hazards.
02 Mechanism
Positive allosteric modulation of GABA-A receptors at the benzodiazepine site, enhancing inhibitory neurotransmission.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 0.5–1 mg | Oral | Potent; small differences in dose matter. |
| Common | 1–2 mg | Oral | Strong, long-lasting sedation and amnesia. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| AnxiolysisReduction in anxiety. | Anecdotal | ||
| SedationMarked, long-lasting drowsiness. | strong, prolonged | Anecdotal | |
| Muscle relaxationReduced muscle tension. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Physical dependenceTolerance and dependence with repeated use; withdrawal can include seizures. | Severe | Common with regular use | Observational | |
| Blackouts / anterograde amnesiaMemory gaps during intoxication, accentuated by potency. | Moderate | Common at active doses | Anecdotal | |
| Additive respiratory depressionDangerous with opioids or alcohol. | Life-threatening | High risk in combination | Observational |